The Ministry of Health of Russia has officially certified “Rukobia” (fostemsavir), developed by ViiV Healthcare, a pharmaceutical company owned by GSK (76.5%), Pfizer (13.5%), Shionogi (10%), and the Medical Patent Pool (MPP).
Rukobia is a prescription medicine used with other antiretroviral (ARV) medicines to treat HIV-1 in adults who have received several anti-HIV-1 regimens in the past, and have HIV-1 virus that is resistant to many ARV medicines, and are failing their current ARV therapy because it is not working, are not able to tolerate the side effects, or have other safety concerns. The company received FDA approval for use in the US in 2020.